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INTRODUCTION
Friedreich ataxia (FRDA) is an autosomal recessive neurodegen-
erative and cardiac disease, caused by a trinucleotide (GAA) repeat 
expansion in the first intron of the frataxin gene located in chromo-
some 9.1 The mutation in the intron 1 of the frataxin gene leads to 
a reduced expression of the frataxin gene without changing the 
protein. The mechanism of this pathology has been reviewed by 
Pandolfo et al.2,3 Neurons and cardiomyocytes are particularly sensi-
tive to the reduction of frataxin.4–6 Thus, neurological and cardiac 
symptoms appear in or before the second decade of life.7–11 There 
are also some systemic involvements, such as diabetes mellitus and 
scoliosis. Cardiomyopathy and associated arrhythmias lead to early 
death.9,12
Mice homozygous for a conditional frataxin allele (Frda exon 
4 located between 2 LoxP, named FrdaL3/L3) have been crossed by 
Puccio et al.13 with mice heterozygous for the deletion of Frda exon 
4 (Frda L-/L3) that also carried a tissue-specific Cre transgene under 
the control of the muscle creatine kinase (MCK) or the neuron- 
specific enolase (NSE) promoter. The MCK promoter induced a 
knockout of the exon 4 in the heart and the striated muscle and 
the resulting mice were called MCK-cre. The NSE promoter lead 
to a knockout of the Frda exon 4 not only in the brain but also in 
the heart, muscles, kidney, and liver and the resulting mice were 
designated as NSE-cre. These mice reproduced important progres-
sive pathophysiological and biochemical features of the human dis-
ease: cardiac hypertrophy without skeletal muscle involvement. The 
NSE mice also express large sensory neuron dysfunctions without 
alteration of the small sensory and motor neurons.
In the present article, we tested different quantity of virus 
from 6 × 109 virus particles (v.p.) to 6 × 1011 v.p. The injection of 
the virus clearly prolonged the life of the treated mice for all 
the quantity tested. Also, the administration of 6 × 1011 v.p. of an 
adeno-associated virus (AAV)9 coding for the human frataxin to 
the MCK-cre and to the NSE-cre not only increased the expres-
sion of the frataxin protein in these mouse models of FRDA but 
clearly reduced their heart hypertrophy and improved their heart 
function. We are thus proposing that an AAV coding for frataxin 
could be a treatment for FRDA.
RESULTS
Confirmation of the frataxin gene knockout in the experimental 
mice
PCR amplifications of the genomic DNA of various tissues were 
made to verify the KO of the frataxin gene (Supplementary Figure 
S1). The delta allele (L-) resulted in a 263 bp band due to exon 4 exci-
sion. Different organs were analyzed: the muscle (Tibialis anterior), 
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Friedreich ataxia (FRDA) is a genetic disease due to increased repeats of the GAA trinucleotide in intron 1 of the frataxin gene. This 
mutation leads to a reduced expression of frataxin. We have produced an adeno-associated virus (AAV)9 coding for human frataxin 
(AAV9-hFXN). This AAV was delivered by intraperitoneal (IP) injection to young conditionally knockout mice in which the frataxin 
gene had been knocked-out in some tissues during embryogenesis by breeding them with mice expressing the Cre recombinase 
gene under the muscle creatine kinase (MCK) or the neuron-specific enolase (NSE) promoter. In the first part of the study, different 
doses of virus were tested from 6 × 1011 v.p. to 6 × 109 v.p. in NSE-cre mice and all leading to an increase in life spent of the mice. The 
higher and the lower dose were also tested in MCK-cre mice. A single administration of the AAV9-hFXN at 6 × 1011 v.p. more than 
doubled the life of these mice. In fact the MCK-cre mice treated with the AAV9-hFXN were sacrificed for further molecular investi-
gations at the age of 29 weeks without apparent symptoms. Echography analysis of the heart function clearly indicated that the 
cardiac systolic function was better preserved in the mice that received 6 × 1011 v.p. of AAV9-hFXN. The human frataxin protein was 
detected by ELISA in the heart, brain, muscles, kidney, and liver with the higher dose of virus in both mouse models. Thus, gene 
therapy with an AAV9-hFXN is a potential treatment of FRDA.
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the liver, the heart, the kidneys, and the brain. For the MCK-cre 
mice, a delta allele band was observed only in the muscle and in 
the heart corresponding with the specificity of the MCK promoter 
(Supplementary Figure S1b on the left). Sometimes, a very light 
delta band (L-) appeared in the brain of some animals. For the NSE-
cre mice, a delta band was observed in all the investigated tissues 
(the brain, the liver, the heart, the skeletal muscles, and the kidney) 
(Supplementary Figure S1b on the right).
The expression of the frataxin gene was also investigated by 
RT-PCR in several tissues. The upper 332 bp band corresponded to the 
unfloxed frataxin mouse mRNA (Supplementary Figure S1c, left side). 
A second band was observed under 332 bp. As indicated by sequenc-
ing this lower band (designated as floxed band) corresponded to the 
mouse frataxin mRNA deleted of exon 4. For the MCK-cre mice, the 
unfloxed frataxin band was observed in liver, kidney, and brain and 
the floxed band was observed only in muscles and heart.
In the NSE-cre mice, the floxing of the conditional frataxin gene 
was different (Supplementary Figure S1c right side). For all these 
mice, we observed only the floxed mRNA in the heart. In the other 
organs of these NSE-cre mice, most of the time two bands were 
observed indicating that the frataxin gene was not floxed in all cells. 
The floxed frataxin allele was more abundant in the brain than in the 
muscle, liver, and kidneys. These results indicated that NSE-cre mice 
have a complete KO of the frataxin gene in the heart and a partial 
KO in the other organs investigated.
PART 1: study on the NSE-cre mice
Behavior of the experimental mice without the AAV9-hFXN treatment. 
The NSE-cre were initially normally active but had signs of kyphosis 
and they walked on the tip of their toes (score 1, Table 1). After weaning, 
they showed a rapid degeneration of their physical condition. They 
progressively became more curved, their fur appeared ruffled (bent 
back, bristly hairs) and finally their general activity decreased. At the 
end of their life, they lost progressively some body weight and had 
difficulties to move, to walk, to breathe and to feed themselves (score 
3 and 4, Table 1). They had to be sacrificed due to ethical concerns 
around 35 ± 18 days (mean ± SEM) (Figure 1).
Effects of AAV9-FXN treatment on body weight. The growth curve of 
the NSE-cre was followed for the treated and not treated mice. The 
NSE-cre curve was significantly lower than that of the L3/L3 mice 
(Figure 1). When these mice received the AAV9-hFXN at 5–9 days, 
their growth curves were improved compared to the NSE-cre mice 
that did not receive the treatment. This was observed for all the viral 
doses tested. However, they did not reach the body weight of the 
L3/L3 mice for male (Figure 1a) and female mice (Figure 1b). Only 
the males receiving 6 × 1011 v.p. (d1/10) seem to follow the curve of 
the L3/L3 but there were only three mice in this group.
Table 1 Animal score
Score Characteristics Action
0 Lively and active animal None.
Smooth coat
No lack of comfort Observe once per week.
1 Mouse moves normally but 
often on the tip of their toes.
Wet food into the cage.
May have the back lightly 
curved.
Observe daily.
2 Mouse moves normally but 
on the tip of their toes.
Wet food into the cage.
Mouse mostly lively. Observe twice a day.
Hair slightly spiky.
Back curved.
Could have a abnormal 
breathing but not difficult.
3 Mouse has difficulties to 
walk and moves less.
Wet food into the cage.
Back curved and hair very 
spiky.
Observe twice a day.
Difficulties to eat.
Could have an abnormal 
and difficult breathing.
Should be sacrificed 
within 4 hours.
4 Mouse does not move or 
moves with pain.
Should be sacrificed 
immediately.
Very spiky hair.
Could have lifeless, sunk or 
closed eyes.
Difficulties to eat.
Could have a breathing 
insufficiency.
Figure 1  Evolution of neuron-specific enolase (NSE)-cre mouse weight. 
The body weight of the different groups of mice was followed until their 
sacrifice. In a, the male mice: L3/L3 (n = 26), NSE-cre mice treated with 
the AAV9-hFXN at 6 × 1011 v.p. (named AAV9-hFXN; n = 12), at 3 × 1011 v.p. 
(named d1/2; n = 0), at 6 × 1010 v.p. (named d1/10; n = 3), at 3 × 1010 v.p. 
(named d1/20; n = 2), at 1.2 × 1010 v.p. (named d1/50; n = 5), at 6 × 109 v.p. 
(named d1/100; n = 3) and the untreated mice (named no treatment; n 
= 33). In b, the female mice: L3/L3 (n = 20), NSE-cre mice treated with the 
AAV9-hFXN at 6 × 1011 v.p. (n = 17), at 3 × 1011 v.p. (n = 3), at 6 × 1010 v.p. (n 
= 2), at 3 × 1010 v.p. (n = 3), at 1.2 × 1010 v.p. (n = 3), at 6 × 109 v.p. (n = 4) and 
the untreated mice (n = 33). The untreated NSE-cre had the lowest body 
weight. The growth curve of the NSE-cre mice was clearly improved by 
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Detection of human frataxin after the AAV9-hFXN treatment. An 
AAV9 coding for the human frataxin (AAV9-hFXN) was injected 
IP in NSE-cre mice between 5 and 9 days of age. Their organs 
were collected at the time of the sacrifice. A PCR for the human 
frataxin was made on genomic DNA to detect the presence of the 
human frataxin transgene. This transgene was detected in all the 
investigated tissues (i.e., brain, heart, muscle, kidney, and liver) for 
6 × 1011 v.p. injected (Figure 2a on the left). Dilutions 1/10 and 1/20 
were also tested in the same conditions. The human frataxin band 
was observed in muscle, liver, and heart for these dilutions. The 
intensity of the band decreased with the dilutions, but the strongest 
band was always detected in the heart. RT-PCR also produced 
similar results (Figure 2a on the right). For an injection of 6 × 1011 
v.p., human frataxin expression was observed in all tissues tested, 
with the strongest band in the heart and the intensity of the bands 
were decreasing with the dilutions of the virus.
Finally, the presence of human frataxin protein was investigated 
using a specific dipstick test. No human frataxin was detected in 
L3/L3 mice and in model mice that were injected with saline rather 
than with the AAV9-hFXN (data not shown). However, the hFXN 
was detected in all tissues from both mouse models injected with 
6 × 1011 v.p of AAV9-hFXN (Figure 2b). With the dilution, the intensity 
of the band diminished in all organs except for the heart where the 
intensity remained strong with the different quantities of virus. The 
human frataxin was not observed in the brain for the three lower 
doses of virus, probably because the limit of detection was reached.
Effects of AAV9-hFXN treatment on mouse survival. A score from 0 
to 4 was created to estimate the NSE-cre health (0 corresponding to 
no symptoms and 4 a state of health requiring immediate sacrifice; 
cf Supplementary Information). The NSE-cre mice were evaluated 
every day after the weaning (21 days) because of the great variability 
of the progression of the disease and mortality. When the mice were 
treated with the AAV9-hFXN, the score was around 1.5 at 21 days, 
while the average score was 2.0 for the untreated NSE-cre. However, 
the score of the treated NSE-cre mice decreased (i.e., they were less 
sick) over the following 3 days while the score of the untreated mice 
increased. The scores were significantly different between the two 
groups between 21 and 40 days. The time between the injection 
and the first score of 0 (i.e., no symptom) was also estimated. In 
average, 20 ± 5.8 days after the viral injection for 6 × 1011 v.p. and 
15.7 ± 2.6 days for 6 × 109 v.p., all the symptoms of the disease had 
disappeared (Figure 3a). Some mice reached a 0 score but were 
later scored at 0.5 or 1. For the estimation of the time where no 
symptoms were detected, we considered the first time the mouse 
score reached 0. However, these NSE mice have later developed 
Figure 2 Detection of the hFXN transgene in various tissues of neuron-specific enolase (NSE)-cre. (a) on the left: The human frataxin (hFXN) transgene 
was detected by polymerase chain reaction (PCR) in the DNA of muscles (M), L (liver), heart (H), kidney (K), and brain (B) of mice injected with AAV-hFXN 
at 6 × 1011 v.p. (named AAV-hFXN) and in 6 × 1010 v.p. (named d1/10) and in 3 × 1010 v.p. (named d1/20). a, on the right: The expression of the human 
frataxin transgene (hFXN) was then detected by RT-PCR in all these tissues. (b) Finally, an ELISA test (Dipstick) was made to detect the human FXN 
protein in skeletal muscle (M), liver (L), heart (H), kidney (K), and brain (B). The human frataxin protein was estimated in these tissues in NSE-cre mice 
treated with AAV9-hFXN at 6 × 1011 v.p. (n = 9), at 3 × 1011 v.p. (n = 4), at 6 × 1010 v.p. (n = 3), at 3 × 1010 v.p. (n = 3), at 1.2 × 1010 v.p. (n = 3), at 6 × 109 v.p. (n = 
3). The presence of human frataxin was strong with the highest dose of virus and decreased in the tissues with the dilutions except for the heart where 
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nervous system symptoms, their score rapidly increased and they 
had to be sacrificed for ethical concerns.
The survival of the mice was also evaluated after the AAV9-hFXN 
injection. It is important to note that some mice were sacrificed 
voluntary to investigate cardiac parameters while other had to be 
sacrificed for ethical concerns. For treated NSE-cre mice injected 
with 6 × 1011 v.p., 6 mice from the 18 mice in that group were vol-
untary sacrificed at 96 and 122 days. Despite the voluntary sacrifice 
of some mice for the two highest quantities of virus injected, the 
average survival of the NSE-cre mice was significantly increased 
from 35 ± 18 days (untreated) to 103 ± 32 and 135 ± 40 with the 
injection of 6 × 1011 v.p. and 3 × 1011 v.p. of AAV9-hFXN respectively 
(Figure 3b). All the quantities of virus led to a significant increase 
of the survival compared to the untreated mice. The survival was 
doubled with v.p. dilutions from 1/100 to 1/20. The 6 × 1011 v.p dose 
of virus increased the survival by roughly threefolds.
Effects of AAV9-hFXN treatment on cardiac function. At the time 
of sacrifice, the weight of the heart of the mice treated or not with 
the different doses of AAV9-hFXN was measured (Figure 4a). There 
was no significant heart weight difference between the L3/L3, the 
NSE-cre, and the treated NSE-cre mice with 6 × 1011 v.p. to 6 × 1010 
v.p. (d1/10). However, because of the difference in body weight, 
we also expressed the heart weight as a percentage of the total 
body weight (Figure 4b). This percentage was 0.57 ± 0.11 for L3/
L3 mice. The effect of the treatment was strong for all the NSE-cre 
treated mice, the percentage passing from 1.91 ± 0.61 (not treated) 
to 0.81 ± 0.23 with the AAV9-hFXN treatment 6 × 1011 v.p. All the 
treated mice were significantly different from the nontreated mice 
and not significantly different from the L3/L3 mice.
PART 2: study on the MCK-cre mice
The results obtained in the first part with the NSE-cre mice showed 
a strong presence of human frataxin protein in the heart of the 
treated mice with a single injection of 6 × 109 v.p. For the study of 
the MCK-cre mice, we thus decided to focus only on the highest and 
lowest doses of virus because the major health problem of the MCK-
cre is due to the deletion of frataxin in heart.
Effects of AAV9-FXN treatment on body weight. The MCK-cre mice 
followed the same body weight growth curve as the L3/L3 mice. 
The growth curve of these MCK-cre mice was not modified by the 
administration of AAV9-hFXN at 6 × 1011 v.p. and 6 × 109 v.p. (d1/100) 
(Figure 5a,b).
Detection of human frataxin after the AAV9-hFXN treatment. 
The presence of the virus was detected by PCR in genomic DNA 
(Figure  6a on the left) and by RT-PCR (Figure 6a on the right) 
following a treatment with 6 × 1011 v.p. As for NSE-cre mice, the 
strongest band was observed for the heart tissue. The presence of 
Figure 3 Improved life survival of the neuron-specific enolase (NSE)-cre 
mice treated with AAV9-frataxin. (a) A score was created to evaluate daily 
the health of the NSE-cre mice. The score goes from 0, which corresponds 
to a normal phenotype, to 4, where the signs of discomfort (loss of 
weight, difficulties to walk or to feed) led to the sacrifice of the mice. The 
score started after weaning, at 21 days. The delay between the injection 
and a score of zero (no symptoms) was determined for all doses of AAV9-
hFXN at 6 × 1011 v.p. (named AAV9-hFXN; n = 14), at 3 × 1011 v.p. (named 
d1/2; n = 7), at 6 × 1010 v.p. (named d1/10; n = 5), at 3 × 1010 v.p. (named 
d1/20; n = 5), at 1.2 × 1010 v.p. (named d1/50; n = 8), at 6 × 109 v.p. (named 
d1/100; n = 6). (b) The survival was also estimated for all these groups. 
The injection of AAV9-hFXN clearly improved the general health of the 
NSE-cre mice for all viral doses (†P ≤ 0.0001): AAV9-hFXN at 6 × 1011 v.p. 
(n = 18), at 3 × 1011 v.p. (n = 5), at 6 × 1010 v.p. (n = 4), at 3 × 1010 v.p. (n = 
5), at 1.2 × 1010 v.p. (n = 8), at 6 × 109 v.p. (n = 6) when compared to the 
untreated mice (n = 58).
a 
b 
















































Figure 4 AAV-hFXN treatment reduced heart hypertrophy in neuron-
specific enolase (NSE)-cre mice. The weight of the mouse heart treated or 
not with the AAV9-hFXN was measured (a) and expressed at sacrifice as 
a percentage of the whole body weight (b). The groups were composed 
of L3/L3 (n = 20), NSE-cre treated with AAV9-hFXN at 6 × 1011 v.p. (named 
AAV9-hFXN; n = 11), at 3 × 1011 v.p. (named d1/2; n = 5), at 6 × 1010 v.p. 
(named d1/10; n = 4), at 3 × 1010 v.p. (named d1/20; n = 5), at 1.2 × 1010 v.p. 
(named d1/50; n = 8), at 6 × 109 v.p. (named d1/100; n = 6) and untreated 
mice (n = 27). The weight of the heart was significantly different from the 
control L3/L3 and from the untreated mice for the three lowest quantity 
of virus (*P < 0.05; d1/20, d1/50, and d1/100) (a). The normalized weight 
was similar to that of L3/L3 for all the treated mice and significantly 
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human frataxin protein was also detected with the dipstick method 
(Figure 6b). Following the injection of 6 × 1011 v.p. of AAV9-hFXN, the 
presence of frataxin was observed in all tissues tested, the stronger 
bands being in muscle, liver, and heart. Following the administration 
of 6 × 109 v.p., the human frataxin protein was still observed in all 
the organs except in the brain where no protein was detected. 
However, the frataxin concentrations were lower than following the 
administration of the higher quantity of virus.
Effects of AAV9-hFXN treatment on survival and cardiac function. 
The MCK-cre mice had no behavioral difference with the L3/L3 mice 
when they were young. Indeed, their behavior and body weight 
gain were similar to those of L3/L3 mice. However, the mouse health 
regressed suddenly after 50 days. They had periods of difficulty to 
breathe, to walk and within 24–48 hours they had to be sacrificed 
due to ethical concerns. The age of sacrifice varied between 71 ± 20 
days (mean ± SEM) (Figure 7a). 10 MCK-Cre mice treated with 
6 × 1011 v.p. of AAV9-hFXN were voluntary sacrificed at 203 or 251 
days. For MCK-cre mice, the survival went from 71 ± 20 days without 
treatment to 194 ± 67 days following a 6 × 1011 v.p. AAV treatment 
(Figure 7a). Both doses of AAV9-hFXN (i.e., 6 × 1011 v.p. and 6 × 109 
v.p.) significantly improved the survival of these mice. The weight of 
the heart was also measured as well as the body weight. The heart 
weight of MCK-cre was significantly higher than that of control L3/
L3 mouse heart, due to a clear cardiac hypertrophy (Figure 7b). Both 
doses of AAV9-hFXN reduced heart weight. The heart weight was 
expressed as a percentage of the total body weight. This percentage 
was higher for the untreated mice than for the control L3/L3 mice 
(Figure 7c). It was however significantly decreased with both doses 
of virus.
PART 3: behavior study and echocardiography on NSE-cre and 
MCK-cre injected with 6 × 1011 v.p. of AAV9-hFXN
Behavior and echocardiography tests were also made on untreated 
mice and mice treated with the highest dose of 6 × 1011 v.p. of AAV9-
hFXN because human frataxin was detected in the mouse brain 
only at that dose.
Effects of AAV9-hFXN treatment on behavior. The following behavior 
parameters were analyzed: distance traveled, immobile time, rear 
duration, and episode immobile (Figure 8a–d). The behavior of the 
MCK-cre mice was not different from that of L3/L3 mice (Figure 8). 
On the contrary, the NSE-cre mice were clearly different from the L3/
L3 for all these parameters. These mice were less active (Figure 8a,c). 
However, after the injection with the AAV9-hFXN, the NSE-cre mice 
(NSE-cre-AAV) got back to normal activities (Figure 8a–d). The NSE-
cre treated mice appeared quite normal and were clearly different 
from the NSE mutants that did not receive the AAV9-FXN treatment.
Other more specific tests were also made on these mice but 
no significant effects were observed between the treated and 
untreated mice (data not shown).
Effects of AAV9-hFXN treatment on cardiac function. 
Echocardiography examination was also made on these mice 
(Figure  9). The injection of AAV9-hFXN ameliorated significantly 
the stroke volume (a), the cardiac output (b) and the systolic (c) and 
diastolic (d) diameters of the MCK-cre mice (Figure 9, on the left). The 
relative wall thickness, the fractional shortening and the fractional 
ejection were also ameliorated in the MCK-cre treated mice 
(Supplementary Figures S2 and S3). The injection of AAV9-hFXN 
had no effect on the stroke volume and the cardiac output of NSE-
cre mice. However, the treatment restored the diastolic and systolic 
diameters of the heart of NSE-cre mice (Figure 9c,d, on the right).
DISCUSSION
FRDA is due to a reduced expression of frataxin following an expan-
sion of a trinucleotide (GAA) repeat in intron 1.1 Frataxin is a mito-
chondrial protein and its reduction leads in turn to a mitochondrial 
miss-function (for a review of the pathological mechanism, see 
Pandolfo et al.3). There is increased oxidative stress and accumula-
tion of iron in the mitochondria. These changes, particularly the 
increased oxidative stress, lead to cell death, including neurons and 
cardiomyocytes. This progressive cell death results in several neuro-
logical and cardiac symptoms.
The transgenic NSE-cre and MCK-cre mouse models were devel-
oped by Dr Puccio.13 The MCK-cre model of FRDA has floxed frataxin 
gene in the heart and the muscles in which the Cre recombinase 
is expressed. We have detected no expression of mouse frataxin in 
these tissues. However, for the NSE-cre mice, there was a complete 
knockout of the mouse frataxin gene only in the heart and a partial 
KO in the muscle, liver, kidney, and brain. Our results in the MCK-
cre and the NSE-cre confirmed the previously published results.13 
Figure 5 Evolution of muscle creatine kinase (MCK)-cre mouse weight. 
In a, the growth curves of the male mice: L3/L3 mice (n = 26), MCK-cre 
untreated (no treatment; n = 67) and MCK-cre mice treated with the 
AAV9-hFXN at 6 × 1011 v.p. (AAV9-hFXN; n = 8) as well as at 6 × 109 v.p. 
(d1/100; n = 2). In b, the growth curves of the female mice: L3/L3 mice 
(n = 20), MCK-cre untreated (n = 47) and MCK-cre mice treated with the 
AAV9-hFXN at 6 × 1011 v.p. (n = 7) as well as at 6 × 109 v.p. (n = 3). There was 
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The MCK-cre mice were used for this study because they have more 
specific cardiac symptoms of FRDA compared to the NSE-cre mice, 
which lack of frataxin in almost every organ. The NSE-cre mice were 
however useful because of its severe early onset symptoms, which 
permitted to detect rapidly clear differences following an effective 
treatment with the AAV9-hFXN.
This absence of frataxin expression starts during the embryo-
logical development of the conditional KO mice bred with a mouse 
expressing the Cre gene. Our results confirmed the previous report 
that the NSE-cre mice have a lower than normal weight and develop 
progressive neurological symptoms and hunched stance.13
The age of death of the untreated MCK-cre mice was similar in 
all research groups (76 ± 10 days)13 and 65 ± 10 days14 versus 71 ± 20 
days for us. In the case of the NSE-cre mice, the age of death was 
a little higher in our results 35 ± 18 days than in those of Dr Puccio 
(24 ± 9 days)13 and Dr Payne groups (28 ± 2 days).15 The difference in 
mouse survival could be due to the difference in the mouse hous-
ing (the accessibility to the food and after the weaning, a wild type 
female remained in the cage with the sick mice to help them to 
make a nest and to take care of themselves).
Both mutants are thus very severe models of the disease and 
have a short life expectancy without treatment. Our results clearly 
demonstrated that the IP administration of an AAV9 vector cod-
ing for human frataxin significantly increased up to two times the 
life expectancy of both NSE-cre and MCK-cre mice with high and 
low quantity of virus. Vyas et al.15 also increased by around 50% the 
survival of the NSE-cre mice by intrainjection of Tat-frataxin protein 
twice a week with a maximum of 88 days of survival. In our study, 
among the 18 NSE-cre mice treated with 6 × 1011 v.p. AAV9-hFXN, 
only one died at 46 days, the other ones lived more than 74 days 
and five were sacrificed for the cardiac analysis at 96 and 121 days. 
The lower AAV dose (6 × 109 v.p.) increased significantly the survival 
of NSE-cre mice. The longer survival was obtained for the three 
highest viral doses even if some mice were voluntarily sacrificed for 
experiments. For the MCK-cre mice, among the 14 mice treated with 
6 × 1011 v.p. AAV9-hFXN, only 4 died between 80 and 116 days, 10 
were sacrificed for cardiac analysis (4 mice at 203 days, 4 mice at 251 
days, and 2 mice at 253 days). Perdomini et al.14 also increased sig-
nificantly the survival of the MCK-cre mice through an intravenous 
injection of 5.4 × 1013 vg/kg of AAVrh10 (this corresponds to about 
5 × 1011 v.p. per young mouse) coding for for the human frataxin. 
The viral dose injected per mouse or rat was around 1011 g.c. ou v.p. 
per animal in many publications.14,16,17 Bish et al.17 also tested various 
dilutions of the AAV vector (2.5 × 1011, 2.5 × 1010, and 2.5 × 109 viral 
particules. They found that the expression in heart was diminished 
with the dilution contrarily to our results with the NSE-cre where 
the frataxin protein stayed at high quantity for all the dilution of 
virus tested in heart (Figure 2b). Our study clearly showed that with 
a quantity of 6 × 1011 v.p., the frataxin protein was detected in the 
brain of mice but with only 6 × 109 v.p., the heart function was still 
improved as well as the survival of the mice. This suggests that the 
quantity of virus injected could be adjusted to the targeting organ, 
with a lower quantity for the heart and a higher quantity to reach 
the brain.
In Friedreich’s patient, a hypertrophic cardiomyopathy was 
observed due to a thickening of the ventricular walls.18 In general, 
the global systolic function is preserved but at the end of their life, 
the ejection fraction is reduced. The MCK-cre and NSE-cre model 
reproduce the cardiomyopathy as well as the biochemical features 
observed in FRDA patients.13–15 In the MCK model, after 6 weeks, this 
cardiomyopathy is characterized by an increased in left ventricular 
end-distolic chamber dimensions and left ventricular end-systolic 
Figure 6 Detection of the hFXN transgene in various tissues of muscle creatine kinase (MCK)-cre. (a) The human frataxin (hFXN) transgene was detected 
by polymerase chain reaction (PCR) not only in the DNA of muscles (M), L (liver), heart (H), kidney (K), and brain (B) of the mice injected with AAV9-hFXN 
at 6 × 1011 v.p. (on the left) but also the expression of human frataxin (on the right). (b) Finally, an ELISA test (Dipstick) was made to detect the human 
FXN protein in the tissues of MCK-cre mice treated with AAV9-hFXN at 6 × 1011 v.p. (named AAV9-hFXN; n = 8) and at 6 × 109 v.p. (named d1/100; n = 4). 
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chamber dimension and a reduction in left ventricular fractional 
shortening,19 which were also observed in our study. In our stud-
ies, the average age of the untreated MCK-cre mice tested for echo-
cardiography was 70 days (59–71 days for the 11 mice). However, 
one mouse was evaluated at 131 days corresponding to a late stage 
since the untreated mice lived an average of 71 days.
The percentage of fractional ejection was significantly reduced 
from 51% for the wt mice to 32% for the MCK-cre mice, a symp-
tom similar to that of the FRDA patients. The AAV9-hFXN treatment 
permitted to increase the fractional ejection to 43% without com-
pletely restoring the function (Supplementary Figure S3). The same 
observation was made for the stroke volume, which was reduced 
in FRDA patient. The stroke volume of wt mice was 0.042 ml, this 
decreased to 0.02 ml in MCK-cre mice. The treatment of these mice 
when they were only 5–9 days old with AAV9-hFXN prevented the 
reduction of the stroke volume. Thus, these treated MCK-cre mice 
had an average stroke volume of 0.034 ml. The fractional heart 
shortening is reduced in the MCK-cre mice. This means that the 
left ventricle in diastole and in systole varies less during the cardiac 
cycle. The reason for this reduced variation is that the ventricle is 
contracting less during the systole. The stroke volume is the blood 
volume ejected by the left ventricle during the systole while the car-
diac output corresponds to this volume multiplied by the heart fre-
quency to obtain the ejected volume per minute. The stroke volume 
of the MCK-cre mice is about only haft of that of normal mice. Thus 
the MCK-cre mice have cardiac insufficiency. The fractional shorten-
ing, the stroke volume and the cardiac output were all significantly 
improved in the MCK-cre mice treated with AAV9-hFXN.
For the NSE-cre mice, less difference were observed compared to 
the wt mice. In our study, the stroke volume as well as the cardiac 
output was significantly lower for the NSE-cre mice while the ejec-
tion fraction and the fractional shortening was similar between the 
wt and the NSE mice (Figure 8 and Supplementary Figures S2 and 
S3). The same conclusion was made by Vyas et al.15 study by com-
paring wt and NSE-cre mice. They used Tat-frataxin protein to treat 
the disease, and even though the survival of the treated mice was 
increased, these cardiac parameters were not significantly amelio-
rated, and this was also the case in our study for the stroke volume 
and the cardiac output.
However, it should be noted that although the AAV9-hFXN was 
detected as well as the protein in the brain of our mice injected with 
6 × 1011 v.p., the mice did develop nervous symptoms (abnormal leg 
Figure 7 Improved life survival of the muscle creatine kinase (MCK)-cre mice treated with AAV9-frataxin. (a) Without treatment, the MCK-cre had to be 
sacrificed at an average age of 71 ± 20 days (no treatment; n = 37). However, the MCK-cre injected intraperitoneally (i.p.) with 6 × 1011 v.p. or 6 × 109 v.p. 
of AAV9-hFXN were voluntary sacrificed after 180 days for further investigation. Thus, the average age of sacrifice of the treated mice was significantly 
higher than that of the untreated mice for both MCK-cre groups treated at the higher (n = 14) and the lower (n = 5) viral doses. The weight of the mouse 
heart treated or not with the AAV9-hFXN was measured at the time of sacrifice (b) and expressed as a percentage of the whole body weight (c). The 
heart weight of the MCK-cre was higher than that of the L3/L3; this hypertrophy was prevented by the AAV9-hFXN treatment. The normalized heart 
weights of the untreated MCK-cre mice were higher than that of the wt mice. The treatment with AAV9-hFXN ameliorated the percentage compared 
to the control and the lowest quantity led to the same value than the control L3/L3. The *** indicate significant difference at P less than 0.0001. P ≤ 
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movement when they were hold up by the tail (see Supplementary 
Video S1). These symptoms are potentially the consequence of 
insufficient expression of frataxin in the brain of these mice start-
ing during early embryogenesis. It is reported that the NSE mice 
have spongiform degeneration as in brain cortex and the deletion 
of frataxin in other organs like the liver should explain the short 
lifetime.13,20
The recent article from Dr. Puccio’s group showed that the intra-
venous injection of an AAVrh10-hFXN in 3 weeks old MCK mice also 
increased the survival and preserved of the heart’s activity. The virus 
was particularly present in the heart, the liver, and the dorsal root 
ganglia but the expression was lower in skeletal muscles.14 Piras et 
al.16 indicated that AAV9 can deliver a shRNA with good efficacy to 
the heart while Aschauer et al.21 indicated that it can infect neurons 
very effectively. Our genomic analysis indicated that the AAV9-hFXN 
injection resulted in strong presence of the human frataxin transgene 
in muscle, heart, and brain. The expression of human frataxin in the 
different organs parallels the intensity of bands in the genomic result. 
Nevertheless, the presence of human frataxin protein was also strong 
in liver in our mice. This strong expression of frataxin in the liver 
was also observed in a recent article from Puccio’s group14 by using 
a AAVrh10 to deliver the human frataxin to mice. Compared to this 
study, we demonstrated that an IP injection of an AAV9 led not only 
to a high detection of frataxin in heart, in liver (which was observed in 
Puccio’s group) but also in skeletal muscle.
The mode of administration as well as the serotype of the AAV 
used are both very important for the diffusion and the expression 
in the organism. To treat specifically the heart, some experiments 
where made with a direct injection of AAV in the thoracic cham-
ber or directly into the pericardia tissue. Piras et al.16 showed that 
the AAV9 were detected in heart and in lung but the expression 
was only observed in the heart. Another article from Bish et al.17 
compared different AAV serotypes 1–9 injected intrapericardially. 
They found that AAV9 led to the higher expression in heart. They 
also shown that even through following intrapericardiac injection, 
the presence of the virus was detected in all other tissues it was a 
strongly expressed only in the heart.
In view to all the results obtained and with the different modes of 
injection described previously, we conclude that a simple IP injec-
tion is as effective as a venous or a direct cardiac injection to obtain a 
significant effect in the heart and in the brain, at least with the AAV9 
serotype. Therefore, our results suggest that the administration of 
an AAV9 coding for human frataxin may be able to increase the 
expression of frataxin in the brain and the heart of FRDA patients. 
The increased expression of the frataxin may reduce or prevent the 
development of nervous system and cardiac symptoms.
The exposition to an AAV has been shown to induce an immune 
response.22–24 Thus, many humans have preformed antibodies to 
AAV and this has led to the failure of the early clinical trials conducted 
with AAV2.
25 However, a recent clinical trial for hemophilia B using an 
Figure 8 Cage activity. The activity was estimated for the different groups of mice (L3/L3, n = 11; muscle creatine kinase (MCK)-cre, n = 15; MCK-cre 
treated with 6 × 1011 v.p. of AAV9-hFXN, n = 7; neuron-specific enolase (NSE)-cre, n = 4 and NSE-cre treated with 6 × 1011 v.p. of AAV9-hFXN, n = 5) as the 
distance traveled in meters (a), the mean rear duration in seconds (b), the duration of immobility in seconds (c), and the number of immobile episodes 
(d). The injection of AAV9-hFXN significantly improved the distance traveled (a) and the mean rear duration (b) of the NSE-cre treated mice. The *** 
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AAV8 has been very successful because most humans do not have 
pre-formed antibodies to this serotype of the virus.26 Puccio et al.14 
detected no immune reaction in mice after one intra-venous injec-
tion of AAVrh10-hFXN. Although an immune response will probably 
develop in the FRDA patients following the systemic delivery of an 
AAV8, AAV9, or AAVrh10 coding for frataxin, this will not be a prob-
lem since no readministration of the virus will be required. The main 
problem facing this potential therapy is that the large-scale produc-
tion of AAV vector under GMP conditions remains difficult.
MATERIALS AND METHODS
AAV vector construction and viral vector production
The AAV vector plasmids were made and packaged in AAV9 
capsids as previously described.27–29 Specifically, the AAV vec-
tor plasmid dsAAV-CB-hFrataxin (AAV9-hFXN) was derived from 
plasmid dsAAV-CB-GFP30 by replacing the GFP gene with the 
human frataxin coding sequence, which was polymerase chain 
reaction (PCR) amplified with the following primers: Forward: 5′ 
TAGTGCTAGCCACCATGTGGACTCTCGGGCGCCG 3′ and reverse: 5′ 
ACTGAAGCTTATCAAGCATCTTTTCCGGAATAG 3′. The forward primer 
also contained the Kozak sequence GCCACC before the start codon 
ATG and the reverse primer had two stop codons at the end of the 
coding sequence. The vectors were then packaged in AAV9 capsid 
using the adenovirus-free, triple plasmid DNA transfection method 
and purified twice with CsCl gradient (1). AAV vector genome (v.g.) 
copies/ml were titrated by a standard dot-blot assay.
Reproduction of the mutant mice
Supplementary Figure S1a summarizes the different mouse geno-
types (Puccio 2001). Mice homozygous for a conditional allele of 
Frda (FrdaL3/L3) and heterozygous FrdaL3/L:NSE-cre (NSE-cre), which 
carried a tissue-specific Cre transgene under the control of the neu-
ron-specific enolase (NSE), were gifts from Dr M Payne laboratory 
(Indiana University School of Medicine) following the permission 
of Dr Puccio (Institut de Génétique et de Biologie Moléculaire et 
Cellulaire, Illkirch, France) who generated these mice.13 These mice 
were bred in our animal facility to produce FrdaL-/L-:NSE-Cre (NSE-
cre). In these mice, both conditional knockout frataxin genes are 
Figure 9 AAV9-frataxin treatment improved heart function of muscle creatine kinase (MCK)-cre mice. Stroke volume (a), cardiac output (b), systolic 
(c), and diastolic (d) diameters were evaluated by echocardiography under isoflurane anesthesia. All these parameters were improved in the MCK-cre 
that received 6 × 1011 v.p. of AAV9-hFXN compared to untreated MCK-cre mice. In neuron-specific enolase (NSE)-cre mice, only the systolic and diastolic 
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knocked out in the neurons and in other tissues expressing the Cre 
gene. Two hemizygous males B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J 
were also purchased from the Jackson laboratory (stock # 006475) 
and used to generate FrdaL-/L-:MCK-cre (MCK-cre). In these mice, 
both conditional KO frataxin genes are knocked in skeletal muscle 
fibers and in cardiac cells. For the experiments, FrdaL3/L3 mice were 
used as control mice in many experiments. All the experiences were 
approved by the animal care committee of the Centre Hospitalier 
de l’Université Laval.
The FrdaL3/L3 mice have the completed mouse frataxin gene but 
there is LoxP site on each side of the exon 4. When these mice 
were bred with mice expressing the Cre gene, mice without exon 
4 were obtained because the Cre enzyme had cut both LoxP sites 
and deleted exon 4. This frataxin allele deleted of exon 4 is called 
the delta allele (L-). The deletion of exon 4 led to a nonfunctional 
frataxin gene.
Two mouse models were used in this study: the MCK-cre and NSE-
cre mice. Homozygous conditional knockout mice FrdaL3/L3 were 
bred with heterozygote mice FrdaL3/+ also expressing the Cre gene 
under the MCK promoter. Some of the offsprings were homozygous 
for the conditional KO frataxin gene and also had the MCK-cre gene. 
Therefore these mice had both frataxin genes KO in their skeletal 
muscles and heart starting during embryogenesis. These mice are 
designated as “MCK-cre” mutants. MCK-cre mice (injected or not 
with saline) were used as untreated controls. Similarly, homozygous 
conditional knockout mice FrdaL3/L3 were bred with heterozygote 
mice FrdaL3/+ also expressing the Cre gene under the NSE promoter. 
Some of the offsprings were homozygous for the conditional KO 
frataxin gene and also had the NSE-cre gene. The mice were named 
“NSE-cre”.
Administration of AAV9-hFXN
A genotype analysis was made in 4 days old mice using the tail tip. 
The MCK-cre or NSE-cre mice were then injected with a single intra-
peritoneal (IP) injection of viral particles in 60 µl of saline between 5 
and 9 days. Control mice were injected with saline. A point of surgi-
cal glue was applied to the skin just after removing the needle to 
keep the liquid inside the mice. In the first part of the study, different 
quantities of viral particles were injected in NSE-cre mice: 6 × 1011, 
3 × 1011 (d1/2), 6 × 1010 (d1/10), 3 × 1010 (d1/20), 1.2 × 1010 (d1/50), 
and 6 × 109 (d1/100) v.p. For the second part of the study, only the 
highest and lowest doses were tested (6 × 1011 and 6 × 109 viral par-
ticles) on MCK-cre mice. In the third part, only the higher quantity of 
virus was used in NSE-cre and MCK-cre mice for more specific evalu-
ations, such as echocardiography.
Mouse evaluation
The weight of the mice was evaluated after weaning and until their 
death. An estimation of the mouse behavior was done each week for 
the MCK-cre and twice a day for the NSE-cre mice because of the sever-
ity of their disease. Their health was scored from 0 (normal behavior) 
to 4 (severe cardiac or respiratory insufficiency (Table 1) requiring 
immediate sacrifice due to ethical concern. At the time of euthanasia, 
the body and heart weight was measured. Different tissues (Tibialis 
anterior muscle, the liver, the kidneys, the heart, and the brain) were 
recovered and directly frozen in liquid nitrogen for analyzes.
DNA extraction
DNA was extracted from different tissues (muscle, liver, heart, kid-
ney, and brain). Briefly, a part of the recovered tissue was incubated 
with 50 µl of proteinase K (10 mg/ml) in a lysis buffer at 56 °C until 
the solution became clear. Digested tissues were then mixed with 
500 µl of a solution of phenol/chloroform/isoamyl alcohol (25:24:1) 
and centrifuged 3 minutes at 13,000 rpm. The upper solution was 
recovered and mixed with the same volume of chloroform and cen-
trifuged again. The upper solution was recovered and 50 µl of 5 mol/l 
sodium chloride was added before the addition of 1 ml of 100% etha-
nol. After a 8-minute centrifugation at 13,000 rpm, the pellets were 
washed in 70% alcohol before another centrifugation. The pellets 
were then dried before the suspension of the DNA in sterile water. 
PCR was performed with 50 ng of the genomic DNA solution using 
primers specific for delta and human frataxin (hFXN). The annealing 
temperatures and the PCR parameters are presented in the Table 2.
RT-PCR
The total RNA was extracted using the Trizol reagent from a part of 
the different tissues. First-strand cDNAs were synthesized using 1 µg 
total RNA with the oligo (dt) primer and Superscript III reverse tran-
scriptase. PCR was performed with 2 µl of the cDNA solution using the 
primers specific for β-actin (reference gene), human frataxin (hFXN), 
and mouse frataxin (mFXN). The PCR parameters are presented in 
Table 2. PCR products were then separated by electrophoresis in 1% 
agarose gels and were stained with RedSafe (Chembio, St Albans, 
Herts AL2 3UG). A picture of the gel was obtained with the GelDoc 
program (BioRad, Mississauga, Ontario, Canada) under UV light.
Open-field activity
Mice were placed in a rectangular cage made of clear Plexiglas 
identical in size to their home-cage (width: 18 cm, length: 28 cm, 
height: 12 cm) and equipped with a video-tracking system (Side 
Table 2 Polymerase chain reaction parameters
Gene name Primer sequences Tm Nb of cycles Enzyme
Delta FXN allele (Fw) (Rev) 5′-CTG TTT ACC ATG GCT GAG ATC TC-3′ 62,5 35 Terra
5′-GTA GCT GGC TGG GAA ATG AA-3′
mFXN (Fw) (Rev) 5′-CTG CGT GGT GCA TTT GAG GAA C-3′ 62 35 Taq 360
5′-CAT GCA GAG ACA CGC CGT CAT GA-3′
hFXN (Fw) (Rev) 5′-AAC GTG GCC TCA ACC AGA TTT G-3′ 62 30 Taq 360
5′-TAA GGC TTT AGT GAG CTC TGC G-3′
m β-actin (Fw) (Rev) 5′-ATA CGC TGC GCT GGT CGT C-3′ 58 30 Taq 360
5′-AGG ATG GCG TGA GGG AGA GC-3′
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view, Any maze, Stoelting, Wood Dale, IL). Each mouse was placed 
in this cage without its usual bedding for a single 2-minute session 
with the experimenter out of its view. Distance traveled, time spent 
immobile and rearing frequency and duration were recorded. After 
each trial, fecal boli were removed and the floor was wiped clean 
with a damp cloth and dried.
Quantification of the frataxin protein by ELISA
The human frataxin protein in various mouse tissues was quanti-
fied using the Dipstick Array of Abcam (cat # ab109881, Cambridge, 
MA). This is an immunologic sandwich assay using two monoclonal 
antibodies specific for two antigens present in the mature form of 
frataxin. One antibody is immobilized on the nitrocellulose mem-
brane of the dipstick in a thin line perpendicular to the length of 
the dipstick while the other is gold-conjugated with gives the red 
signal proportional to the level of frataxin. To compare and to pool 
the different organs and mice, a range from 1 to 10 was established 
to “semi-quantify” the density of the frataxin band.
Evaluation of heart function by echocardiography
A complete M-Mode, 2D, and Doppler echocardiogram was per-
formed on the mice under 1.5% inhaled isoflurane anesthesia using 
L17-7 and S12 probes with a HD11XE echograph (Philips Medical 
Imaging, Andover, MA). Different parameters (left ventricular dimen-
sions, fractional shortening, stroke volume, and cardiac output and 
frequency) were evaluated as previously described.31,32 At the end of 
the protocol and under anesthesia, the heart was quickly removed, 
freed from connective tissue, and weighed.
Statistical analyses
The experimental values were presented as means ± SD. Statistical 
analysis was performed using the StatView statistical package 
(StatView 5; SAS Institute, Cary, NC). Comparisons of different vari-
ables between groups were performed using analysis of variance 
techniques. Differences were considered statistically significant at P 
≤ 0.05*; P ≤ 0.001**; P ≤ 0.0001***.
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